CTKB Stock - Cytek Biosciences, Inc.
Unlock GoAI Insights for CTKB
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $200.45M | $193.01M | $164.04M | $127.95M | $92.84M |
| Gross Profit | $111.11M | $109.43M | $100.97M | $79.14M | $51.71M |
| Gross Margin | 55.4% | 56.7% | 61.6% | 61.9% | 55.7% |
| Operating Income | $-20,523,000 | $-27,845,000 | $-1,804,000 | $9.16M | $13.66M |
| Net Income | $-6,020,000 | $-12,148,000 | $2.58M | $3.00M | $19.41M |
| Net Margin | -3.0% | -6.3% | 1.6% | 2.3% | 20.9% |
| EPS | $-0.05 | $-0.09 | $0.02 | $0.03 | $0.02 |
Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system, which leverages full spectrum profiling technology to further broaden potential applications across cell analysis. The company also provides reagents and kits, including cFluor reagents, which are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, which are automated plate loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific region; and through distributors or sales agents in European, Latin American, the Middle Eastern, and the Asia-Pacific countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 2nd 2025 | Morgan Stanley | Resumed | Equal Weight | $6 |
| May 9th 2025 | TD Cowen | Downgrade | Hold | $4 |
| January 31st 2025 | Goldman | Downgrade | Sell | $4.5← $7 |
| December 14th 2023 | Stephens | Initiation | Overweight | $9 |
| July 19th 2023 | Raymond James | Initiation | Market Perform | - |
Earnings History & Surprises
CTKBEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Feb 26, 2026 | $0.02 | — | — | — |
Q4 2025 | Nov 5, 2025 | $0.01 | $-0.01 | -200.0% | ✗ MISS |
Q3 2025 | Aug 6, 2025 | $-0.02 | $0.01 | +150.0% | ✓ BEAT |
Q2 2025 | May 8, 2025 | $-0.04 | $-0.09 | -125.0% | ✗ MISS |
Q1 2025 | Feb 27, 2025 | $0.05 | $0.07 | +40.0% | ✓ BEAT |
Q4 2024 | Nov 5, 2024 | $0.00 | $0.01 | +166.7% | ✓ BEAT |
Q3 2024 | Aug 6, 2024 | $-0.03 | $-0.08 | -166.7% | ✗ MISS |
Q2 2024 | May 8, 2024 | $-0.05 | $-0.05 | 0.0% | = MET |
Q1 2024 | Mar 13, 2024 | $0.03 | $0.07 | +133.3% | ✓ BEAT |
Q4 2023 | Nov 7, 2023 | $-0.33 | $0.01 | +103.0% | ✓ BEAT |
Q3 2023 | Aug 8, 2023 | $-0.01 | $0.01 | +200.0% | ✓ BEAT |
Q2 2023 | May 9, 2023 | $-0.01 | $-0.03 | -100.0% | ✗ MISS |
Q1 2023 | Feb 28, 2023 | $0.05 | $0.07 | +40.0% | ✓ BEAT |
Q4 2022 | Nov 9, 2022 | $0.02 | $0.04 | +100.0% | ✓ BEAT |
Q3 2022 | Aug 10, 2022 | $0.02 | $0.03 | +80.0% | ✓ BEAT |
Q2 2022 | May 11, 2022 | $0.00 | $0.01 | +300.0% | ✓ BEAT |
Q1 2022 | Feb 23, 2022 | $0.04 | $0.05 | +20.0% | ✓ BEAT |
Q4 2021 | Nov 8, 2021 | $0.02 | $0.02 | -14.3% | ✗ MISS |
Q3 2021 | Sep 3, 2021 | — | $0.02 | — | — |
Q3 2021 | Jul 27, 2021 | — | $0.00 | — | — |
Latest News
Piper Sandler Maintains Overweight on Cytek Biosciences, Lowers Price Target to $7.5
➖ NeutralCytek Biosciences shares are trading higher after the company reported better-than-expected Q3 financial results.
📈 PositiveCytek Biosciences shares are trading higher after the company reported better-than-expected Q3 financial results.
📈 PositiveCytek Biosciences Affirms FY2025 Sales Guidance of $196.000M-$205.000M vs $196.252M Est
📈 PositiveCytek Biosciences Q3 EPS $(0.04) Beats $(0.05) Estimate, Sales $52.293M Beat $51.489M Estimate
📈 PositiveCytek Biosciences Announces The Relocation Of Its European Headquarters To A New Facility In Amsterdam's Life Sciences District
📈 PositiveFrequently Asked Questions about CTKB
What is CTKB's current stock price?
What is the analyst price target for CTKB?
What sector is Cytek Biosciences, Inc. in?
What is CTKB's market cap?
Does CTKB pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to CTKB for comparison